{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:10:31Z","timestamp":1793945431330,"version":"4.8.0"},"reference-count":36,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Automated insulin delivery (AID) systems represent a major advancement in type 1 diabetes (T1D) management, particularly in pediatric populations. However, real-world evidence comparing their effectiveness to conventional multiple daily injection (MDI) therapy in youth remains limited. This study aimed to evaluate the impact of transitioning from MDI therapy to AID systems on glycemic control in children and adolescents with T1D, and to explore potential differences based on baseline HbA1c levels and device type. Materials and Methods: In this single-center, retrospective observational study, 76 children and adolescents with T1D were evaluated before and after switching from MDI to either the Medtronic MiniMed\u2122 780G or Tandem t:slim X2\u2122 Control-IQ system. Glycemic control was assessed using continuous glucose monitoring (CGM)-derived metrics at three time points: the last 15 days of MDI therapy (T0), 15 days after (T1), and 6 months after (T2) AID initiation. Statistical comparisons were conducted across time points and between subgroups stratified by baseline HbA1c and AID system. Results: Significant improvements in glycemic control were observed as early as 15 days after AID initiation, with sustained benefits at 6 months. Time in range (TIR) increased from 62.0% at baseline to 76.7% at 15 days and 75.8% at 6 months, and time in tight range (TITR) from 39.8% to 53.9% at T1 and 52.1% at T2 (both p &lt; 0.001). Improvements were more pronounced in participants with higher baseline HbA1c (+16.9% for TITR and +22.3% for TIR). No significant differences in glycemic outcomes were observed between device groups, although algorithm-driven differences in insulin delivery patterns were noted. Total daily insulin dose and BMI increased significantly over time (p &lt; 0.001 and p = 0.008, respectively). Conclusions: AID therapy leads to rapid and sustained improvements in glycemic control among youth with T1D, particularly in those with suboptimal baseline control. These benefits highlight the clinical value of AID systems, while also emphasizing the need for monitoring potential metabolic impacts.<\/jats:p>","DOI":"10.3390\/medicina61091602","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T07:46:17Z","timestamp":1757058377000},"page":"1602","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of Automated Insulin Delivery Systems in Children and Adolescents with Type 1 Diabetes Previously Treated with Multiple Daily Injections: A Single-Center Real-World Study"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8664-1025","authenticated-orcid":false,"given":"Bruno","family":"Bombaci","sequence":"first","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Calderone","sequence":"additional","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Di Pisa","sequence":"additional","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"La Rocca","sequence":"additional","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Torre","sequence":"additional","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Salzano","sequence":"additional","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4369-7798","authenticated-orcid":false,"given":"Stefano","family":"Passanisi","sequence":"additional","affiliation":[{"name":"Department of Human Pathology and Developmental Age \u201cG. Barresi\u201d, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1210\/endrev\/bnac022","article-title":"Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice","volume":"44","author":"Phillip","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1159\/000543034","article-title":"International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies\u2014Insulin Delivery","volume":"97","author":"Biester","year":"2024","journal-title":"Horm. Res. Paediatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/dia.2021.0203","article-title":"Real-World Performance of the MiniMedTM 780G System: First Report of Outcomes from 4120 Users","volume":"24","author":"Lepore","year":"2022","journal-title":"Diabetes Technol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/dom.14714","article-title":"Comparison of MiniMed 780G system performance in users aged younger and older than 15\u2009years: Evidence from 12,870 real-world users","volume":"24","author":"Arrieta","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-025-06366-x","article-title":"One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: A prospective observational cohort study","volume":"68","author":"Keymeulen","year":"2025","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/dia.2023.0341","article-title":"Real-World Use of Control-IQ Technology Is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis Than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study","volume":"26","author":"Graham","year":"2024","journal-title":"Diabetes Technol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Morrison, A.E., Chong, K., Senior, P.A., Lam, A., and Palumbo, P. (2022). A scoping review of Do-It-Yourself Automated Insulin Delivery system (DIY AID) use in people with type 1 diabetes. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271096"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/pedi.13454","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents","volume":"23","author":"Libman","year":"2022","journal-title":"Pediatr. Diabetes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1177\/19322968221085273","article-title":"A glycemia risk index (GRI) of hypoglycemia and hyperglycemia for continuous glucose monitoring validated by clinician ratings","volume":"17","author":"Klonoff","year":"2023","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s13300-023-01501-6","article-title":"Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780G\u2122 in Children, Adolescents and Young Adults: A Systematic Review","volume":"15","author":"Passanisi","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s13300-024-01618-2","article-title":"Safety and Psychological Outcomes of Tandem t:Slim X2 Insulin Pump with Control-IQ Technology in Children, Adolescents, and Young Adults with Type 1 Diabetes: A Systematic Review","volume":"15","author":"Mameli","year":"2024","journal-title":"Diabetes Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"110678","DOI":"10.1016\/j.diabres.2023.110678","article-title":"The efficacy of automated insulin delivery systems in children and adolescents with type 1 diabetes Mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"199","author":"Michou","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111621","DOI":"10.1016\/j.diabres.2024.111621","article-title":"Glucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: A multicenter real-world observational study","volume":"210","author":"Cherubini","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/dia.2023.0373","article-title":"Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a new CGM Metric in Children and Adolescents with Type 1 Diabetes using Different Treatment Modalities","volume":"26","author":"Passanisi","year":"2024","journal-title":"Diabetes Technol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e3826","DOI":"10.1002\/dmrr.3826","article-title":"Time In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologies","volume":"40","author":"Schiaffini","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e230077","DOI":"10.1001\/jamanetworkopen.2023.0077","article-title":"Association of Achieving Time in Range Clinical Targets with Treatment Modality Among Youths with Type 1 Diabetes","volume":"6","author":"Dovc","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2337\/dc23-2311","article-title":"Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents with Type 1 Diabetes: A 1-Year Real-World Study","volume":"47","author":"Passanisi","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Seget, S., Chobot, A., Tarasiewicz, M., Bielawska, A., Rusak, E., Ochab, A., Polanska, J., and Jarosz-Chobot, P. (2024). Glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system 2-year prospective, observational, two-center study. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1332418"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2337\/dc24-0916","article-title":"Sustained 3-Year Improvement of Glucose Control with Hybrid Closed Loop in Children with Type 1 Diabetes While Going Through Puberty","volume":"47","author":"Bismuth","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/dia.2021.0097","article-title":"One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology","volume":"23","author":"Breton","year":"2021","journal-title":"Diabetes Technol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Santova, A., Plachy, L., Neuman, V., Pavlikova, M., Petruzelkova, L., Konecna, P., Venhacova, P., Skvor, J., Pomahacova, R., and Neumann, D. (2023). Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: Real-life registry-based study. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1283181"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112070","DOI":"10.1016\/j.diabres.2025.112070","article-title":"Transitioning between automated insulin delivery systems: A focus on personalisation","volume":"222","author":"Chico","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bassi, M., Patti, L., Silvestrini, I., Strati, M.F., Ponzano, M., Minuto, N., and Maggi, D. (2023). One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1099024"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1111\/dom.15791","article-title":"Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes","volume":"26","author":"Piona","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/dom.15344","article-title":"Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics","volume":"26","author":"Henry","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: An international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2337\/dc15-2344","article-title":"Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas","volume":"39","author":"Pinsker","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2337\/ds18-0100","article-title":"Automated Insulin Delivery Algorithms","volume":"32","author":"Cinar","year":"2019","journal-title":"Diabetes Spectr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1111\/dom.15217","article-title":"Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes","volume":"25","author":"Shannon","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(22)00212-1","article-title":"Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): A randomised controlled study","volume":"10","author":"Choudhary","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Castorani, V., Rigamonti, A., Frontino, G., Morotti, E., Sandullo, F., Scialabba, F., Arrigoni, F., Dionisi, B., Foglino, R., and Morosini, C. (2024). Turning the tides: Achieving rapid and safe glucose control in adolescents with suboptimally controlled type 1 diabetes using advanced hybrid closed loop systems. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1243565"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2337\/dc22-1971","article-title":"Impact of Advanced Hybrid Closed Loop on Youth with High-Risk Type 1 Diabetes Using Multiple Daily Injections","volume":"46","author":"Boucsein","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/dia.2023.0364","article-title":"Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes","volume":"26","author":"Criego","year":"2024","journal-title":"Diabetes Technol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/dtom.2025.0022","article-title":"A Systematic Review and Metanalysis on the Impact of Automated Insulin Delivery Systems on Body Mass Index in Youths with Type 1 Diabetes and Potential Predictors","volume":"1","author":"Franceschi","year":"2025","journal-title":"Diabetes Technol. Obes. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON). Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr. Rev."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1602\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:39:52Z","timestamp":1760035192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091602"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091602","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}